Cargando…

Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy

INTRODUCTION: The administration of mifepristone, followed by misoprostol, is widely used for medical abortion. Many studies have demonstrated home abortion to be safe in pregnancies up to 63 days of gestation, and recent data support its safety when extended to more advanced pregnancies. We studied...

Descripción completa

Detalles Bibliográficos
Autores principales: Podolskyi, Volodymyr, Gemzell‐Danielsson, Kristina, Maltzman, Lena L., Marions, Lena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072251/
https://www.ncbi.nlm.nih.gov/pubmed/36933004
http://dx.doi.org/10.1111/aogs.14549
_version_ 1785019343961063424
author Podolskyi, Volodymyr
Gemzell‐Danielsson, Kristina
Maltzman, Lena L.
Marions, Lena
author_facet Podolskyi, Volodymyr
Gemzell‐Danielsson, Kristina
Maltzman, Lena L.
Marions, Lena
author_sort Podolskyi, Volodymyr
collection PubMed
description INTRODUCTION: The administration of mifepristone, followed by misoprostol, is widely used for medical abortion. Many studies have demonstrated home abortion to be safe in pregnancies up to 63 days of gestation, and recent data support its safety when extended to more advanced pregnancies. We studied the efficacy and acceptability of home use of misoprostol up to 70 days of gestation in a Swedish setting and compared the outcomes between pregnancies with a gestational age of up to 63 days and pregnancies with gestational age 64–70 days. MATERIAL AND METHODS: This prospective cohort study was performed between November 2014 and November 2021 at Södersjukhuset and Karolinska University Hospital, Stockholm, and some patients were also recruited from Sahlgrenska University Hospital, Göteborg and Helsingborg Hospital. The primary outcome was the rate of complete abortions and was defined as complete abortion without any need for surgical or medical intervention and assessed by clinical assessment, pregnancy test and/or vaginal ultrasound. Secondary objectives were assessed by daily self‐reporting in a diary and included pain, bleeding, side effects and women's satisfaction and perception of home use of misoprostol. A comparison of categorical variables was made with Fisher's exact test. The significance level was set to a p‐value ≤0.05. The study was registered at Clinicaltrials.gov on July 14, 2014 (NCT02191774). RESULTS: During the study period we enrolled 273 women opting for medical abortion with home use of misoprostol. In the early group, up to 63 days of gestation, 112 women were included with a mean gestational length of 45 days and in the late group, 64–70 days of gestation, 161 women with a mean gestations length of 66.3 days were included. Complete abortion occurred in 95% (95% CI 89–98) of women in the early group and in 96% (95% CI 92–99) in the late group. No differences were found regarding side effects and acceptability was similarly high in both groups. CONCLUSIONS: Our results show high efficacy and acceptability of medical abortion when misoprostol is administered at home up to 70 days of gestation. This supports previous findings about maintained safety when misoprostol is administered at home even past a very early pregnancy.
format Online
Article
Text
id pubmed-10072251
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100722512023-04-05 Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy Podolskyi, Volodymyr Gemzell‐Danielsson, Kristina Maltzman, Lena L. Marions, Lena Acta Obstet Gynecol Scand Original Research Articles INTRODUCTION: The administration of mifepristone, followed by misoprostol, is widely used for medical abortion. Many studies have demonstrated home abortion to be safe in pregnancies up to 63 days of gestation, and recent data support its safety when extended to more advanced pregnancies. We studied the efficacy and acceptability of home use of misoprostol up to 70 days of gestation in a Swedish setting and compared the outcomes between pregnancies with a gestational age of up to 63 days and pregnancies with gestational age 64–70 days. MATERIAL AND METHODS: This prospective cohort study was performed between November 2014 and November 2021 at Södersjukhuset and Karolinska University Hospital, Stockholm, and some patients were also recruited from Sahlgrenska University Hospital, Göteborg and Helsingborg Hospital. The primary outcome was the rate of complete abortions and was defined as complete abortion without any need for surgical or medical intervention and assessed by clinical assessment, pregnancy test and/or vaginal ultrasound. Secondary objectives were assessed by daily self‐reporting in a diary and included pain, bleeding, side effects and women's satisfaction and perception of home use of misoprostol. A comparison of categorical variables was made with Fisher's exact test. The significance level was set to a p‐value ≤0.05. The study was registered at Clinicaltrials.gov on July 14, 2014 (NCT02191774). RESULTS: During the study period we enrolled 273 women opting for medical abortion with home use of misoprostol. In the early group, up to 63 days of gestation, 112 women were included with a mean gestational length of 45 days and in the late group, 64–70 days of gestation, 161 women with a mean gestations length of 66.3 days were included. Complete abortion occurred in 95% (95% CI 89–98) of women in the early group and in 96% (95% CI 92–99) in the late group. No differences were found regarding side effects and acceptability was similarly high in both groups. CONCLUSIONS: Our results show high efficacy and acceptability of medical abortion when misoprostol is administered at home up to 70 days of gestation. This supports previous findings about maintained safety when misoprostol is administered at home even past a very early pregnancy. John Wiley and Sons Inc. 2023-03-18 /pmc/articles/PMC10072251/ /pubmed/36933004 http://dx.doi.org/10.1111/aogs.14549 Text en © 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Podolskyi, Volodymyr
Gemzell‐Danielsson, Kristina
Maltzman, Lena L.
Marions, Lena
Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title_full Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title_fullStr Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title_full_unstemmed Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title_short Effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
title_sort effectiveness and acceptability of home use of misoprostol for medical abortion up to 10 weeks of pregnancy
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072251/
https://www.ncbi.nlm.nih.gov/pubmed/36933004
http://dx.doi.org/10.1111/aogs.14549
work_keys_str_mv AT podolskyivolodymyr effectivenessandacceptabilityofhomeuseofmisoprostolformedicalabortionupto10weeksofpregnancy
AT gemzelldanielssonkristina effectivenessandacceptabilityofhomeuseofmisoprostolformedicalabortionupto10weeksofpregnancy
AT maltzmanlenal effectivenessandacceptabilityofhomeuseofmisoprostolformedicalabortionupto10weeksofpregnancy
AT marionslena effectivenessandacceptabilityofhomeuseofmisoprostolformedicalabortionupto10weeksofpregnancy